Twist Bioscience Co. (NASDAQ:TWST) Receives $51.22 Consensus Price Target from Analysts

Shares of Twist Bioscience Co. (NASDAQ:TWST) have earned an average recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $51.22.

Several brokerages have recently issued reports on TWST. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. The Goldman Sachs Group raised their price objective on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. Evercore ISI increased their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Barclays reduced their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th.

Twist Bioscience Trading Up 0.9 %

NASDAQ TWST opened at $40.60 on Friday. The business’s 50-day moving average price is $43.83 and its 200 day moving average price is $44.80. Twist Bioscience has a twelve month low of $14.42 and a twelve month high of $60.90. The company has a market capitalization of $2.36 billion, a PE ratio of -12.08 and a beta of 1.77.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company had revenue of $81.50 million for the quarter, compared to analysts’ expectations of $77.40 million. During the same quarter in the previous year, the company earned ($1.01) earnings per share. The company’s revenue was up 27.7% on a year-over-year basis. Equities analysts predict that Twist Bioscience will post -3.13 EPS for the current year.

Insider Buying and Selling

In related news, SVP Paula Green sold 1,137 shares of the stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the completion of the transaction, the senior vice president now owns 88,837 shares of the company’s stock, valued at approximately $3,547,261.41. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Twist Bioscience news, SVP Paula Green sold 1,137 shares of the firm’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41. Following the completion of the transaction, the senior vice president now directly owns 88,837 shares of the company’s stock, valued at $3,547,261.41. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Patrick John Finn sold 2,885 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $115,198.05. Following the completion of the sale, the chief operating officer now owns 168,327 shares in the company, valued at approximately $6,721,297.11. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,300 shares of company stock valued at $1,801,822 in the last quarter. Company insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in TWST. Signaturefd LLC lifted its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the last quarter. EdgeRock Capital LLC acquired a new stake in Twist Bioscience during the second quarter worth about $43,000. Blue Trust Inc. lifted its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Twist Bioscience in the second quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.